Clinical Trials

EndocrineGastrointestinalGenitourinaryNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

288 enrolled

Phase 3 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

259 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07165886 2025-09-10

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Phase 2/3 Recruiting

243 enrolled

Phase 3 Active not recruiting

Gastroenteropancreatic Neuroendocrine Tumors

NCT03049189 2025-05-30

COMPETE

309 enrolled

Neuroendocrine Tumors

NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4 Completed

61 enrolled 9 charts

Pancreatic Neuroendocrine Tumors

NCT01524783 2021-08-05

RADIANT-4

Phase 3 Completed

302 enrolled 16 charts

Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

NCT01263353 2020-12-21

COOPERATE-1

Phase 1 Completed

36 enrolled

EndocrineGenitourinaryNETThoracic

Carcinoid Tumor

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00688623 2019-01-25

RAMSETE/CDE16

Phase 2 Completed

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase 4 Completed

246 enrolled 16 charts

Neuroendocrine Tumors

NCT01374451 2016-12-20

COOPERATE-2

Phase 2 Terminated

160 enrolled 17 charts

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Terminated

62 enrolled 7 charts

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01324492 2014-12-30

\MACS1304

Phase 1 Completed

16 enrolled

Lung Neuroendocrine Neoplasm

NCT00412061 2014-11-21

RADIANT-2

Phase 3 Completed

429 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase 2 Completed

160 enrolled 17 charts